Welcome to our dedicated page for bioAffinity Tech SEC filings (Ticker: BIAF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
bioAffinity Technologies, Inc. SEC filings document the public-company record for a biotechnology diagnostics issuer with Nasdaq-listed common stock and tradeable warrants. The filings identify the company as an emerging growth company and smaller reporting company and include disclosures tied to CyPath® Lung, laboratory services, operating performance, and securities registration activity.
Recent filings include Form 8-K reports for financial results, Regulation FD presentation materials, product and clinical-case announcements, and annual meeting voting results. The record also covers governance matters such as director elections and equity incentive plan amendments, along with S-1 registration materials describing securities being registered and related issuer classifications.
bioAffinity Technologies, Inc. reported that a new clinical case study shows how its noninvasive CyPath® Lung test helped guide treatment for a 79-year-old high-risk patient with a suspicious lung nodule found on a low-dose CT scan.
The CyPath Lung result was negative, supporting a choice to monitor with annual CT scans instead of performing an invasive biopsy. A follow-up scan later in 2025 showed the nodule had resolved and no pulmonary nodules were present, reinforcing the conservative approach.
CyPath Lung is designed for early lung cancer detection in high-risk patients using sputum analysis, advanced flow cytometry and AI. Clinical study data cited in the case show 92% sensitivity, 87% specificity and 88% accuracy for detecting lung cancer in small nodules under 2 centimeters.
bioAffinity Technologies reported a new clinical case study using its CyPath® Lung diagnostic test in a high-risk 59-year-old smoker with multiple small pulmonary nodules classified as Lung-RADS 3, a category considered probably benign. A negative CyPath Lung result supported continued six-month CT surveillance rather than more invasive procedures.
The company highlights prior clinical results where CyPath Lung showed 92% sensitivity, 87% specificity and 88% accuracy for detecting lung cancer in high-risk patients with nodules under 20 millimeters. The test is a noninvasive, sputum-based Laboratory Developed Test marketed through Precision Pathology Laboratory Services.
bioAffinity Technologies, Inc. filed a current report to furnish updated presentation materials about the company’s operations and performance. Management intends to use these February 2026 presentation slides in meetings, and the materials were posted to the company’s website on February 10, 2026.
The materials are furnished under Regulation FD as Exhibit 99.1 and are expressly not deemed “filed” for liability purposes under the Securities Exchange Act of 1934 or incorporated by reference into other Securities Act or Exchange Act filings.
bioAffinity Technologies filed an 8-K reporting that it has expanded its Medical and Scientific Advisory Board by appointing three nationally recognized pulmonary and lung cancer specialists: Dr. David Ost of MD Anderson Cancer Center, Dr. Daniel Sterman of NYU Langone Health, and Dr. J. Scott Ferguson of the University of Wisconsin School of Medicine and Public Health.
The company develops CyPath® Lung, a noninvasive diagnostic test for early detection of lung cancer in high-risk patients with small indeterminate pulmonary nodules. In clinical studies, CyPath® Lung showed 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer, supporting its role as an added tool to inform clinicians and potentially improve early-stage diagnosis.
bioAffinity Technologies, Inc. has scheduled its 2026 Annual Meeting of Stockholders for April 30, 2026 at its principal executive offices in San Antonio, Texas. The company plans to include at this meeting the proposals from a prior Special Meeting that was convened on December 19, 2025 but adjourned without business because a quorum of common stockholders was not present.
Stockholders who wish to bring business before the 2026 Annual Meeting or nominate directors must deliver written notice to the company’s principal executive offices by February 14, 2026, in accordance with the detailed requirements of the company’s Amended and Restated Bylaws.
bioAffinity Technologies, Inc. reported that its wholly owned laboratory subsidiary, Precision Pathology Laboratory Services, has successfully maintained its accreditation from the College of American Pathologists. The continued accreditation follows an on-site inspection, indicating the lab met the standards reviewed during that visit.
The company disclosed this development in connection with a press release, which is included as an exhibit to the report.
bioAffinity Technologies, Inc. reported that it will present a scientific poster titled “CyPath® Lung in Practice: From Uncertainty to Clarity and Confidence” at the American Cancer Society National Lung Cancer Roundtable on December 8, 2025. The poster highlights three clinical cases in which CyPath® Lung, a noninvasive sputum-based flow cytometry test, successfully identified Stage 1A lung cancer in patients whose presentations were atypical and diagnostically challenging. The company announced this upcoming presentation in a press release dated December 3, 2025, and has filed both the press release and the poster as exhibits.
bioAffinity Technologies, Inc. (BIAF) filed an 8-K reporting that it furnished a press release containing financial information for the quarter ended September 30, 2025. The company stated the press release is provided under Item 2.02 and is furnished, not filed, and will not be incorporated by reference into other SEC filings.
Exhibits include 99.1 (the press release dated November 14, 2025) and 104 (Cover Page Interactive Data File). The company’s securities listed are Common Stock (BIAF) and Tradeable Warrants (BIAFW) on The Nasdaq Stock Market LLC.
bioAffinity Technologies (BIAF) called a Special Meeting to approve multiple share-related actions. The Board asks stockholders to approve: issuing up to 271,500 shares upon exercise of August 2025 warrants; a warrant anti-dilution reset that could raise the exercisable amount up to 365,620 shares; and a Series B Preferred anti-dilution reset allowing up to 131,884 additional conversion shares. The Board also seeks to amend the 2024 Equity Incentive Plan to 750,000 shares from 66,666; authorize one or more non-public offerings of up to 10 million shares for up to $10,000,000 (at discounts up to 35%) through December 31, 2026; approve any Nasdaq Rule 5635 change of control arising from such offerings; and permit adjournment if needed.
As context, shares outstanding were 3,633,815 as of November 4, 2025. The company states the August 2025 warrants, if exercised for cash, could provide up to approximately $2.9 million in gross proceeds. The Board recommends “FOR” on all proposals.
bioAffinity Technologies (BIAF) filed an 8‑K announcing month‑over‑month growth in CyPath® Lung test volume. The company disclosed the update under Item 8.01 (Other Events) and furnished a detailed press release as Exhibit 99.1. The filing identifies the company’s listed securities on the Nasdaq Capital Market under symbols BIAF (common stock) and BIAFW (warrants). The report date is November 5, 2025.